AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16146256
Drug: 0.05 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mL/kg nebulized L-epinephrine
Trial: 16146256
Drug: 0.5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL/kg nebulized L-epinephrine
Trial: 12163671
Drug: Oral tracer
RxNorm normalized name: Tracleer Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tracer protocol
Trial: 12163671
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) tracer protocol
Trial: 10485962
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg oral)
Trial: 24245707
Drug: Internet-based exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based exposure treatment
Trial: 6703371
Drug: Naloxone (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (after fentanyl, morphine, or meperidine)
Trial: 21045096
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (2 g/d)
Trial: 7678871
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg finasteride daily
Trial: 10210385
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg finasteride daily in men with prostates larger than 40 cc
Trial: 2103193
Drug: 5‐isosorbide mononitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐isosorbide mononitrate (20 mg)
Trial: 391626
Drug: 0.025% oxymetazoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% oxymetazoline ophthalmic solution
Trial: 23307507
Drug: Standard Colonoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Colonoscopy (SC) and Colon Capsule Endoscopy (CCE)
Trial: 21979997
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with meso‐zeaxanthin (10.6 mg), lutein (5.9 mg), and zeaxanthin (1.2 mg)
Trial: 17933885
Drug: Occupational health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational health intervention including consultation and possible referral to specialist treatment.
Trial: 12092748
Drug: Ciprofloxacin alone
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin alone (20 mg/kg) in Rat Study 1
Trial: 12092748
Drug: Ciprofloxacin with
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin with calcium chloride (20 mg/kg) in Rat Study 2
Trial: 12092748
Drug: Ciprofloxacin alone
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin alone (400 mg) in Study 1 (volunteer study)
Trial: 12092748
Drug: Ciprofloxacin with
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin with calcium polycarbophil (400 mg + 1200 mg) in Study 2 (volunteer study)
Trial: 392699
Drug: Fluoride supplement
RxNorm normalized name: Fluoride supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride supplement in sugar products (10 mg F as NaF per kg of sugar) and NaHCO3 + KH2PO4 mixture in candies (substituting for 2.5% of sugar).
Trial: 392699
Drug: Fluoride supplements
RxNorm normalized name: Fluoride supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride supplements in test subjects.
Trial: 27664141
Drug: Community therapists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community therapists delivering family therapy as routine standard of care
Trial: 25679187
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg as atorvastatin calcium tablets
Trial: 23944648
Drug: Intramyocardial injections
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial injections of 2000 μg plasmid vascular endothelial growth factor 165
Trial: 11157143
Drug: IL‐1Ra 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐1Ra 30 mg/day
Trial: 3246167
Drug: Ceftriaxone (CRO:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (CRO: Rocephin) 100 mg/kg/day, once daily
Trial: 3246167
Drug: Ampicillin 160
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin 160 mg/kg/day and chloramphenicol (AMCL) 100 mg/kg/day, every 6 h
Trial: 29530747
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (Ofirmev)
Trial: 29199345
Drug: 3D printing
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D printing implant template (TDPIT group)
Trial: 29199345
Drug: Conventional implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional implant template (CIT group)
Trial: 20373906
Drug: Home delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home delivery of medication
Trial: 7772359
Drug: saline 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline 5 ml
Trial: 31701652
Drug: Triple-drug chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug chemotherapy with lipiodol diameter ratio values between 1 and 3
Trial: 31701652
Drug: Lipiodol ≤10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipiodol ≤10 mL
Trial: 29151359
Drug: Standard EGFR-TKIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard EGFR-TKIs (gefitinib 250 mg once daily or erlotinib 150 mg once daily)
Trial: 24486637
Drug: Sacral neuromodulation
RxNorm normalized name: Boswellia sacra whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacral neuromodulation (InterStim) therapy
Trial: 22520521
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (MED)
Trial: 17977931
Drug: Anodyne monochromatic
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anodyne monochromatic infrared photo energy (MIRE) treatment, used at home every day for 40 min for 90 days.
Trial: 17977931
Drug: Sham treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment, used at home every day for 40 min for 90 days.
Trial: 16214012
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg/d)
Trial: 9781975
Drug: trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimetazidine (20 mg 3 times daily)
Trial: 7876047
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (IVSK) 1.5 million units within 6 hours of onset of chest pain, along with beta-blockers, aspirin, and heparin unless contraindicated.
Trial: 7876047
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy without IVSK.
Trial: 2465851
Drug: Cocaine and
RxNorm normalized name: Cocaine and morphine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine and adrenaline combination
Trial: 30919670
Drug: Melatonin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (0.1 to 0.2 mg/kg, PO, q 12 h for 7 days)
Trial: 30919670
Drug: Placebo (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (150 mg of lactose powder in a capsule, PO, q 12 h for 7 days)
Trial: 28746195
Drug: Facial candling
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Facial candling treatment
Trial: 28746195
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment given)
Trial: 26079533
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion at a rate of 2 μg/kg/min until 48 h after surgery
Trial: 23437535
Drug: Intradermally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermally administered inactivated poliovirus vaccine (0.1 mL) using Biojector 2000
Trial: 23437535
Drug: Intramuscularly administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscularly administered inactivated poliovirus vaccine (0.5 mL) using a pre-filled syringe
Trial: 7955810
Drug: Fluvoxamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100 to 150 mg daily for 16 days)
Trial: 7955810
Drug: Control (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (single oral dose of diazepam 10 mg)
Trial: 26003419
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral therapy (CBT) for children
Trial: 19919878
Drug: Enoxaparin 20mg
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 20mg twice daily for 14 days, started 24-36 hours after surgery
Trial: 18990744
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g GTE per day for 12 months
Trial: 8857072
Drug: Moclobemide 200
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 200 mg b.d. for 14 days
Trial: 8857072
Drug: Selegiline 5
RxNorm normalized name: selegiline 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline 5 mg b.d. for 14 days
Trial: 8857072
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with moclobemide and selegiline
Trial: 1352497
Drug: Salbutamol (full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (full agonist)
Trial: 6391231
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clindamycin and tobramycin
Trial: 30153781
Drug: Protocol-guided strategy
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol-guided strategy using stroke volume variation to guide administration of bolus fluid
Trial: 27128738
Drug: SMART principles
RxNorm normalized name: Muguettine principle
DrugBank: Hydroxycitronellal (DB14187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART principles for goal formulation
Trial: 24783923
Drug: Standardized treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatment with TCM combined with WM (oral Chinese decoctions three times daily for 4 weeks)
Trial: 24783923
Drug: Non-standardized treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-standardized treatment with TCM combined with WM (oral Chinese decoction for promotion of blood circulation for 4 weeks)
Trial: 24783923
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (standardized and non-standardized treatment)
Trial: 19347843
Drug: Highly active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly active antiretroviral therapy (ART)
Trial: 17447222
Drug: Reconcile (fluoxetine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconcile (fluoxetine, 1 to 2 mg/kg/day) plus behavior management
Trial: 14716221
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low-dose nifedipine GITS 20 mg and losartan 50 mg
Trial: 9855086
Drug: Intravenous omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous omeprazole infusion (80 mg + 8 mg/h) for 24 hours followed by 8, 4 or 2 mg/h.
Trial: 9855086
Drug: Intravenous omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous omeprazole infusion (80 mg + 8 mg/h) for 3 days followed by oral omeprazole 20 mg once daily.
Trial: 28263212
Drug: Cabazitaxel (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (4 cycles of 25 mg/m2 + 2 cycles of 20 mg/m2) combined with 188Re-HEDP (40 MBq/kg)
Trial: 28263212
Drug: Cabazitaxel (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (6 cycles of 25 mg/m2) combined with 188Re-HEDP (40 MBq/kg)
Trial: 28263212
Drug: Cabazitaxel monotherapy
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel monotherapy
Trial: 21525848
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRIs) administered orally on single days to assess immediate effects on motor function.
Trial: 16339819
Drug: Enrasentan (60‐90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrasentan (60‐90 mg/day)
Trial: 16339819
Drug: Enalapril (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10‐20 mg/day)
Trial: 14724371
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with lipid-lowering drugs (control group).
Trial: 8766460
Drug: Counselling intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Counselling intervention (6 weekly sessions, educational and problem-solving components, conducted in the family home)
Trial: 3921583
Drug: Combined enteral-parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined enteral-parenteral nutrition (CN)
Trial: 30547287
Drug: MCAF5352A (humanized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCAF5352A (humanized monoclonal antibody targeting IL-17A and IL-17F)
Trial: 23254183
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of F&V by parents
Trial: 21574683
Drug: Manual-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual-guided treatment
Trial: 21574683
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (nonmanualized treatment)
Trial: 18050382
Drug: CF101 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF101 1.0 mg bid for 12 weeks
Trial: 18050382
Drug: CF101 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF101 0.1 mg bid for 12 weeks
Trial: 18050382
Drug: CF101 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF101 4.0 mg bid for 12 weeks
Trial: 18050382
Drug: CF101 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF101 (all doses)
Trial: 16681980
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy and radiotherapy concurrently
Trial: 29722791
Drug: Intravenous NEPA
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous NEPA (fosnetupitant 235 mg plus PALO 0.25 mg)
Trial: 29722791
Drug: Oral NEPA
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral NEPA (netupitant 300 mg plus PALO 0.50 mg)
Trial: 29722791
Drug: Intravenous NEPA
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous NEPA
Trial: 24005613
Drug: PLD 50
RxNorm normalized name: pLDLR-Neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD 50 mg/m² q28 and vandetanib 100 mg/d po
Trial: 12601765
Drug: Commercial subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial subunit vaccine
Trial: 12601765
Drug: Commercial split
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial split virion vaccine
Trial: 9357387
Drug: Debrisoquin 10
RxNorm normalized name: debrisoquin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debrisoquin 10 mg
Trial: 9357387
Drug: Mephenytoin 100
RxNorm normalized name: mephenytoin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mephenytoin 100 mg
Trial: 8387346
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (etoposide, epirubicin, and cis-platinum, days 1-3, every 21 days)
Trial: 8387346
Drug: Chemotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy followed by rhGM‐CSF (10 micrograms/kg/day s.c., days 4-14)
Trial: 8387346
Drug: Chemotherapy preceded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy preceded and followed by rhGM‐CSF (days -17 to -7 for priming, days 4-14 for rescue)
Trial: 8387346
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus rhGM‐CSF rescue
Trial: 8387346
Drug: Chemotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy followed by rhGM‐CSF
Trial: 8387346
Drug: Chemotherapy preceded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy preceded and followed by rhGM‐CSF
Trial: 3523796
Drug: Acebutolol 200
RxNorm normalized name: acebutolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol 200 mg plus hydrochlorothiazide 12.5 mg (SDX)
Trial: 9366100
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg (HCT)
Trial: 18665167
Drug: Irinotecan 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 180 mg m‐2 and cetuximab 500 mg m‐2 q2w
Trial: 20813681
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg Lornoxicam (L8 group)
Trial: 20813681
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg Lornoxicam (L16 group)
Trial: 20813681
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml saline (NS group)
Trial: 11897411
Drug: Intranasal powder
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal powder form of glucagon mixed with microcrystalline cellulose at a ratio of 1:69
Trial: 11897411
Drug: Spray solutions
RxNorm normalized name: Inhalation Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray solutions of glucagon including 1.5% sodium glycocholate
Trial: 11897411
Drug: Spray solutions
RxNorm normalized name: Inhalation Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray solutions of glucagon including 1% sodium caprate
Trial: 9600795
Drug: Clodronate 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1600 mg/day
Trial: 9600795
Drug: Clodronate 2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 2400 mg/day
Trial: 9600795
Drug: Clodronate 800
RxNorm normalized name: clodronic acid 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 800 mg/day
Trial: 8027622
Drug: Adjuvant intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant intraperitoneal 5‐fluorouracil (5‐FU, 500 mg/m2/day) and intravenous leucovorin (60 mg/m2/day)
Trial: 2731750
Drug: sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucralfate 1 g qds (n = 24)
Trial: 2731750
Drug: cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 200 mg tds and 400 mg nocte (n = 22)
Trial: 2731750
Drug: sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucralfate 1 g bd during maintenance
Trial: 2731750
Drug: cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 400 mg nocte during maintenance
Trial: 790548
Drug: Ketoprofen (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (150 mg daily in 3 doses of 50 mg)
Trial: 30690446
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogen (CEE) plus 100 mg micronized progesterone (MP)
Trial: 30690446
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg CEE daily plus 100 mg MP
Trial: 30690446
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg CEE daily plus 10 mg dydrogesterone (DHG)
Trial: 29505549
Drug: Intralipid postconditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid postconditioning (ILPC) - intravenous infusion of 20% intralipid (2 mL/kg) just 10 minutes before aortic cross-unclamping
Trial: 25012422
Drug: 0.25mg oral
RxNorm normalized name: Digoxin 0.25mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25mg oral haloperidol daily for 7 days, followed by placebo for 4 weeks
Trial: 22724108
Drug: Nonthermal atmospheric
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonthermal atmospheric pressure plasma (APP) treatment